TMCnet News
SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against TherapeuticsMD, Inc.Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE: TXMD). Investors who purchased shares between July 7, 2016 and April 9, 2017 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the June 19, 2017 lead plaintiff motion deadline. If you are a shareholder who suffered a loss during the Class Period, click here to participate. Inaddition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA (News - Alert) 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.goldberglawpc.com/, or by email at [email protected]. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The complaint alleges that during the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose: that the Company's New Drug Application ("NDA") submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the FDA's potential approval of the NDA. On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food & Drug Administration identified deficiencies in its NDA for TX-004HR. When this news was announced, the Company's shares fell in value, causing investors harm. Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170420006619/en/ |
